Replies to post #18175 on Ariad Pharmaceuticals Inc fka ARIA

[adreamer]

A Hot Time for Health Care Deals
If mergers activity rises this year, as ever-optimistic deal makers say will happen, health care transactions will help lead the way.

Monday alone brought two major announcements: the long-awaited sale of Pfizer‘s infant nutrition unit to Nestlé for $11.9 billion and AstraZeneca’s $1.26 billion takeover of Ardea Biosciences.

They follow SXC Health Solutions’ $4.4 billion merger with Catalyst Health Solutions; GlaxoSmithKline‘s $2.59 billion unsolicited offer for Human Genome Sciences; the Roche Holding failed $6.2 billion takeover bid for Illumina; and Amylin Pharmaceuticals‘ nascent efforts to sell itself after rejecting a $3.5 billion overture from Bristol-Myers Squibb. All these transpired in the last week or so.

Nestle to Buy Pfizer’s Infant Nutrition Unit for $11.9 Billion
AstraZeneca Reaches $1.26 Billion Deal for Ardea Biosciences
It’s a hot time for health care, even in a merger market that remains slow despite signs of renewed life.

[vidpok45]

Their new drug has a lot of competition from the older drugs colchicine and allopurinol, and the new drug for hyperuricemia, uloric. Surprised they would offer over a billion for the company but I guess the huge uric acid market can sustain another player.